Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927846 | 0.85 | HTR2A (0.44) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL23956100 | 0.82 | HTR7 (0.52) | HTR7HTR2AHTR2CPRMT5 | |
| SCHEMBL23927826 | 0.81 | HTR7 (0.63) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL23956138 | 0.81 | HTR7 (0.67) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL23956140 | 0.81 | HTR7 (0.62) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL23927863 | 0.80 | HTR7 (0.61) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL23956108 | 0.78 | HTR7 (0.38) | HTR7HTR2C | |
| SCHEMBL23927821 | 0.76 | HTR7 (0.53) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL18856964 | 0.71 | HTR2A (0.59) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL8959527 | 0.71 | HTR2A (0.59) | HTR7HTR2AHTR2CCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | HTR7 32/4885HTR2A 5/4885HTR2C 3/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | HTR7 32/4885HTR2A 5/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.